Under construction – not a live service
Sign in
Taking people in CanadaPhase 2

Long-term study of GSK4527226 in people with early Alzheimer's disease

Tests GSK4527226 over the long term in people with early Alzheimer's disease.

Plain-language title generated from the registry record
Registry title: Open-label Extension Study in Participants With Early Alzheimer's Disease

Key facts

Where
Greenfield Park, Ottawa, Peterborough, Sherbrooke, and Toronto, CanadaSee the 5 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with early Alzheimer's disease who finished the treatment period of the parent study NCT06079190. Everyone gets the study medicine GSK4527226.

Age
50 to 85 years
Sex
Men and women can join.
Disease stage
Early Alzheimer's disease, including mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease.
Earlier treatment
Must have completed the treatment period of the parent study NCT06079190. Must not have been permanently stopped early from the study treatment or withdrawn from that study.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Taking or about to start a prohibited medication listed in the protocol
  • Signs of amyloid related imaging abnormalities (ARIA) or cerebral macrohemorrhage that meet the permanent stopping criteria
  • Newly found brain bleeding, brain tumour or other MRI finding that rules out taking part
  • Newly diagnosed cancer or new infection that may affect the central nervous system

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 85 years old?

Source: NCT07105709, who can take part

Where in Canada

  • Greenfield Park, QuebecHospital not named in the registryTaking people
  • Ottawa, OntarioHospital not named in the registryTaking people
  • Peterborough, OntarioHospital not named in the registryTaking people
  • Sherbrooke, QuebecHospital not named in the registryTaking people
  • Toronto, OntarioHospital not named in the registryTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
GlaxoSmithKline
Trial code
NCT07105709
Record updated
2 February 2026
Original description
The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment [MCI] and mild dementia due to AD) who have completed the parent study.Read full original descriptionShow less

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment [MCI] and mild dementia due to AD) who have completed the parent study.

Inclusion: Completion of the Treatment Period in the parent study (NCT06079190); Participants may have missed doses during the Treatment Period or may be on a temporary dose suspension but must not have been permanently discontinued early from study intervention or withdrawn from the parent study; Willing and able to give informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF); Availability of an adult person who has frequent and sufficient contact with the participant, is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits, and signs the study partner ICF; A female participant is eligible to participate if she is not pregnant or breastfeeding, and if of childbearing potential follows contraception requirements outlined in the protocol; A male participant is eligible to participate if he follows contraception requirements outlined in the protocol.

Exclusion: Participant is taking or will be starting a prohibited medication described in the protocol; Other newly identified intracranial hemorrhage aneurysm, vascular malformation, infective lesion, space occupying lesion or brain tumor, or other Magnetic resonance imaging (MRI) findings contraindicating participation in the study; Newly identified infection(s) that may affect the Central nervous system (CNS); New diagnosis of moderate to severe alcohol and/or substance use disorder; Newly diagnosed cancer; Newly identified severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins; Newly identified genetic predisposition for clotting disorder or hemorrhagic disease; QT interval corrected (QTc) assessment at Day 1 that meets the stopping criteria described in the protocol; Evidence of any Amyloid related imaging abnormalities (ARIA) or cerebral macrohemorrhage that meets the permanent discontinuation criteria described in the protocol; Change in participant's ability to tolerate MRI procedures, contraindication to MRI, or any other clinical history or examination finding that would pose a potential hazard in combination with MRI; Any other clinically significant change in health status (which, in the opinion of the investigator, would make the participant unsuitable for participation in the OLE study.

ClinicalTrials.gov NCT07105709